
Breast Cancer
Latest Content

BriaCell Bets an Off-the-Shelf Cell Vaccine Can Extend Life After ADCs in Metastatic Breast Cancer

FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
Latest Videos
Shorts










Podcasts
More News

Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.

The action comes after an advisory panel recommended against approval, saying evidence from the did not support a “clinically meaningful benefit."

A cohort study found lower breast cancer screening odds in the most redlined census tracts, independent of present-day social vulnerability.

Experts discussed biomarker testing, novel cancer therapies, multidisciplinary care, and strategies to expand access.

June 2026 brought 5 FDA firsts across infectious disease, oncology, and rare disease, expanding treatment options and addressing unmet patient needs.

AI-guided breast screening is advancing faster than coverage policy, guidelines, and imaging capacity—raising questions about who qualifies and who pays.

Approval is granted for patients with PIK3CA wild-type disease who progressed after endocrine therapy, based on VIKTORIA-1's improved survival results.

Jennifer Sheng, MD, discusses how consistent follow-up, patient education, and lifestyle interventions improve breast cancer survivorship care.

Kazia Therapeutics advances paxalisib, a dual PI3K/mTOR inhibitor, into triple-negative breast cancer, boosting immunotherapy responses with early promising data.

Breast density raises cancer risk and masks tumors on mammography. Danielle Holt, MD, MSS, explains why density alone shouldn't trigger more imaging.

The FDA approved sacituzumab govitecan-hziy alone or with pembrolizumab as first-line therapy for metastatic triple-negative breast cancer.

FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.

Investigators described the combinations as a potential new standard of care in second-line HR+/HER2− advanced breast cancer.

OPTIMA shows Prosigna guides chemo decisions in high‑risk HR+ early breast cancer, sparing two‑thirds without raising 5‑year recurrence risk.

I-SPY 2.2 of rilvegostomig plus trastuzumab deruxtecan in breast cancer treatment cut chemo use while exposing access issues and disparities.

Nancy Lin, MD, explores MMAI validation needs, turnaround advantages, equity implications, and how payers should approach AI-based diagnostics.

Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy.

















